Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Capital Expenditures (2021 - 2024)

SAB Biotherapeutics' Capital Expenditures history spans 4 years, with the latest figure at $55377.0 for Q4 2024.

  • For Q4 2024, Capital Expenditures fell 18.4% year-over-year to $55377.0; the TTM value through Dec 2024 reached $337262.0, up 71.07%, while the annual FY2025 figure was $933156.0, 176.69% up from the prior year.
  • Capital Expenditures reached $55377.0 in Q4 2024 per SABSW's latest filing, down from $100300.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $3.5 million in Q2 2021 to a low of $21300.0 in Q1 2023.
  • Average Capital Expenditures over 4 years is $852780.4, with a median of $109027.0 recorded in 2022.
  • Peak YoY movement for Capital Expenditures: tumbled 98.43% in 2023, then surged 505.98% in 2024.
  • A 4-year view of Capital Expenditures shows it stood at $2.4 million in 2021, then crashed by 95.01% to $117754.0 in 2022, then tumbled by 42.37% to $67864.0 in 2023, then dropped by 18.4% to $55377.0 in 2024.
  • Per Business Quant, the three most recent readings for SABSW's Capital Expenditures are $55377.0 (Q4 2024), $100300.0 (Q3 2024), and $52511.0 (Q2 2024).